Exosomal DNA Methylation Analysis for Early Disease Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting epigenetic changes in DNA are limited in their ability to accurately diagnose and monitor diseases, particularly cancer, due to the challenges of isolating and analyzing exosomal DNA from bodily fluids.

Innovation Solution

The method involves isolating exosomes from bodily fluids, such as blood, and analyzing the methylation or hydroxymethylation status of DNA molecules within these exosomes using reduced representation bisulfite sequencing to detect disease-specific methylation patterns.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If exosomal DNA is isolated from bodily fluids for disease detection, then measurement precision is improved, but device complexity and difficulty of detecting and measuring increase

Engineering Contradiction:

Improvedisease detection accuracyVSAvoidexosomal DNA analysis difficulty

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent segments the complex task of exosomal DNA analysis into distinct steps: exosome isolation from bodily fluids, DNA extraction from isolated exosomes, and methylation analysis of the extracted DNA. This segmentation reduces the overall difficulty by making each step manageable and optimizable independently.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses isolated exosomes as an intermediary carrier to access and analyze DNA methylation patterns. By targeting exosomes specifically, the method simplifies the detection process compared to analyzing total DNA from bodily fluids, as exosomes protect and deliver intact DNA molecules that retain disease-specific epigenetic marks.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If comprehensive methylation analysis is performed across multiple genomic loci, then measurement precision is improved, but loss of time and productivity decrease

Engineering Contradiction:

Improvemethylation status accuracyVSAvoidanalysis time

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs methylation analysis at specific selected genomic loci rather than comprehensive whole-genome sequencing. By focusing on loci known to be associated with specific diseases or cancer types, the method achieves sufficient diagnostic precision while significantly reducing analysis time and computational resources required.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent employs preliminary selection of target genomic loci based on disease association before performing methylation analysis. This preliminary action allows the method to focus resources on the most informative regions, improving both precision and efficiency by avoiding analysis of irrelevant genomic regions.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS12473598B2Identification of epigenetic alterations in DNA isolated from exosomes

Publication Date: 2025.11.18 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

The present invention provides methods of diagnosing and prognosing disease by analyzing the methylation status of exosomal DNA. In particular, exosomal DNA, in particular exosomal DNA isolated from exosomes that originated from a diseased cell, is analyzed for either a global methylation fingerprint or for a particular methylation status at one or more genomic loci, thereby providing information regarding the disease-state of the originated cell.